The clinical problem: Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC). Lymph node metastasis (LNM) is a critical step in disease progression, strongly associated with poor survival and treatment resistance.
A knowledge gap in the tumor immune microenvironment: While researchers know that the tumor immune microenvironment (TME) plays a key role in cancer spread, little was understood about how the immune landscape specifically changes when LUAD spreads to lymph nodes compared to the primary tumor site.
Study goals: This study used single-cell RNA sequencing (scRNA-seq) combined with machine learning to map immune cell differences between primary LUAD tumors and lymph node metastases - and to build a clinical risk score from those findings.
Data sources used: The team analyzed public datasets including GSE131907 from GEO (scRNA-seq), plus TCGA-LUAD and multiple GEO cohorts for validation of the machine learning prognostic model.
Single-cell RNA sequencing (scRNA-seq): The researchers analyzed scRNA-seq data from GSE131907, which profiles individual cells from both primary tumors and lymph node metastases. This technique reveals the identity and activity of each cell type - something bulk tissue analysis cannot do.
Cell type identification: Using established marker genes, they classified cells into major immune populations including T cells, B cells, natural killer cells, macrophages, dendritic cells, and cancer cells. The relative abundance and activity of each population was compared between primary and metastatic sites.
Machine learning ensemble model: To translate cellular findings into a clinical tool, the team used 10 machine learning algorithms - including random forest, LASSO regression, and support vector machine - to identify genes that best predict lymph node metastasis risk. These were combined into an ensemble model called LNRScore.
Validation across cohorts: The LNRScore model was tested across multiple independent datasets to confirm its ability to stratify patients by prognosis and predict response to immunotherapy.
Macrophage remodeling at metastatic sites: A major discovery was that SPP1+ macrophages (tumor-associated macrophages expressing the secreted phosphoprotein SPP1/osteopontin) are significantly enriched in lymph node metastases compared to primary tumors. These cells actively suppress immune responses.
T cell exhaustion: In lymph node metastases, T cells showed higher levels of exhaustion markers - meaning they were present but functionally unable to attack cancer cells. This contributes to immune escape at metastatic sites.
Reduced anti-tumor immune activity: Natural killer cells and cytotoxic T cells, which normally destroy cancer cells, were less active in lymph node metastases. This creates an immunosuppressive niche that favors cancer cell survival and proliferation.
HMGA1 as a core regulatory gene: Among all the genes analyzed, HMGA1 (High Mobility Group AT-hook 1) emerged as the most central gene driving lymph node metastasis risk. HMGA1 is a chromatin-organizing protein linked to tumor invasion and poor prognosis.
What LNRScore measures: The LNRScore is an ensemble machine learning score derived from 10 algorithms. It integrates the expression of key immune microenvironment genes to assign each LUAD patient a risk level for lymph node metastasis.
High vs. low risk stratification: Patients with high LNRScores had significantly shorter overall survival and disease-free survival compared to low-score patients in both the TCGA-LUAD cohort and multiple GEO validation datasets.
Independent prognostic value: After adjusting for clinical variables such as age, sex, and tumor stage, LNRScore remained an independent predictor of survival - meaning it adds information beyond what standard staging provides.
Immunotherapy response prediction: High LNRScore patients showed different immune checkpoint biomarker profiles, suggesting the score can also guide which patients are likely to benefit from PD-1/PD-L1 immunotherapy.
Primary tumor immunity: Primary lung adenocarcinoma tumors contain a relatively diverse immune cell mixture, including functional cytotoxic T cells that can attack cancer cells. This immune activity is part of why early-stage tumors can sometimes be controlled.
Metastatic immune suppression: In lymph node metastases, the balance shifts decisively toward immune suppression. SPP1+ macrophages dominate, exhausted T cells accumulate, and inflammatory signaling pathways are reprogrammed to protect cancer cells.
Cell-cell communication analysis: Using ligand-receptor interaction analysis (CellChat), the study mapped how cancer cells communicate with immune cells. In metastases, SPP1-mediated signaling from macrophages to other immune cells was particularly prominent.
Implications for therapy: The distinct immune landscape of lymph node metastases means that therapies targeting primary tumors may be insufficient at metastatic sites. Strategies specifically targeting SPP1+ macrophages or reversing T cell exhaustion may be needed.
Risk stratification in clinical practice: LNRScore could be used alongside standard staging to identify patients at highest risk for lymph node spread - enabling more aggressive surveillance or earlier treatment escalation.
Biomarker for immunotherapy selection: Given that high-risk patients have distinct immune profiles, LNRScore may help oncologists predict which patients are most likely to respond to checkpoint inhibitors like pembrolizumab or nivolumab.
HMGA1 as a therapeutic target: HMGA1's central role in driving LNM progression suggests it could be a target for novel therapies. Agents that inhibit HMGA1 activity might reduce metastatic potential in LUAD patients.
Macrophage-targeting strategies: Therapies designed to reprogram SPP1+ macrophages from an immunosuppressive to an immune-activating state represent a promising future direction, particularly for patients with established lymph node metastases.
Retrospective data limitation: The machine learning models were developed and validated using publicly available retrospective datasets. Prospective clinical trials are needed to confirm the clinical utility of LNRScore in real-world settings.
Lack of treatment-specific analysis: The study did not deeply stratify patients by specific treatments received. Future work should analyze LNRScore performance within patients receiving specific targeted therapies or immunotherapy regimens.
Functional validation needed: While scRNA-seq data points to HMGA1 and SPP1+ macrophages as key drivers, experimental studies using cell lines and animal models are needed to confirm these genes causally drive metastasis.
Multi-omic integration: Future studies should integrate scRNA-seq with spatial transcriptomics and proteomics to achieve a more complete picture of how the immune microenvironment is organized in three dimensions within lymph node metastases.